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OBJECTIVE—Maturity onset diabetes of the young type 3
(MODY3) is a consequence of heterozygous germline mutation in
HNF1A. A subtype of hepatocellular adenoma (HCA) is also
caused by biallelic somatic HNF1A mutations (H-HCA), and rare
HCA may be related to MODY3. To better understand a relation-
ship between the development of MODY3 and HCA, we com-
pared both germline and somatic spectra of HNF1A mutations.
RESEARCH DESIGN AND METHODS—We compared 151
somatic HNF1A mutations in HCA with 364 germline mutations
described in MODY3. We searched for genotoxic and oxidative
stress features in HCA and surrounding liver tissue.
RESULTS—A spectrum of HNF1A somatic mutations signiﬁ-
cantly differed from the germline changes in MODY3. In HCA, we
identiﬁed a speciﬁc hot spot at codon 206, nonsense and frame-
shift mutations mainly in the NH2-terminal part, and almost all
amino acid substitutions were restricted to the POU-H domain.
The high frequency of G-to-T tranversions, predominantly found
on the nontranscribed DNA strand, suggested a genotoxic mech-
anism. However, no features of oxidative stress were observed in
the nontumor liver tissue. Finally, in a few MODY3 patients with
HNF1A germline mutation leading to amino acid substitutions
outside the POU-H domain, we identiﬁed a different subtype of
HCA either with a gp130 and/or CTNNB1 activating mutation.
CONCLUSIONS—Germline HNF1A mutations could be associ-
ated with different molecular subtypes of HCA. H-HCA showed
mutations profoundly inactivating hepatocyte nuclear factor-1
function; they are associated with a genotoxic signature suggest-
ing a speciﬁc toxicant exposure that could be associated with
genetic predisposition. Diabetes 59:1836–1844, 2010
H
epatocellular adenoma (HCA) is a rare, benign,
liver tumor frequently associated with oral con-
traception (1,2). HCA usually manifests as a
single tumor, but in some cases, several adeno-
mas are detected in the same patient; when 10 nodules
are identiﬁed in the liver it is called liver adenomatosis (3).
Recently, by the analysis of a large series of patients with
HCAs, we established a new molecular classiﬁcation of
these tumors. Adenomas were classiﬁed according to the
genotype of the tumors, such as the ﬁnding of mutations in
HNF1A,i nCTNNB1-activating -catenin and/or in the
interleukin-6 transducer of signal (IL6ST) activating gp130
(4–8). Close relationships were found between the molec-
ular subgroups deﬁned by genotype and the clinical/
pathologic ﬁndings (4,8). Particularly, HNF1A-mutated
HCAs (H-HCAs) represent a homogeneous group of tu-
mors with marked and diffuse steatosis without signiﬁcant
inﬂammation or cytologic abnormalities (4,8). In these
tumors, downregulation of LFABP1 (encoding liver fatty
acid-binding protein), a gene positively regulated by
HNF1A, may contribute to this phenotype through im-
paired fatty acid trafﬁcking together with an aberrant
promotion of lipogenesis (9).
Heterozygous germline mutations of HNF1A are also
the cause of maturity onset diabetes of the young type 3
(MODY3), a monogenic form of noninsulin-dependent
diabetes (10). A few cases of familial liver adenomatosis
were identiﬁed in patients with MODY3 (5,11,12). In these
patients, one HNF1A mutation was germline, whereas the
other was somatic and occurred only in tumor cells. In
most of these families, penetrance of adenomatosis is low,
and in one of them, we identiﬁed a CYP1B1 heterozygous
germline mutation as a genetic event associated with the
occurrence of HCA (13). Occurrence of HCA in individuals
with MODY3 is rare, and the biologic underpinnings of this
phenomenon remain to be explained.
The HNF1A gene (previously called TCF1) codes for the
transcription factor hepatocyte nuclear factor (HNF)-1.
HNF1 protein recognizes speciﬁc palindromic nucleotide
DNA sequences and interacts with DNA as either a ho-
modimer or a heterodimer with HNF1 (14,15). HNF1
plays an important role by regulating the expression of
many key liver genes involved in glucidic metabolism,
lipidic transport, and detoxication (16–19). HNF1 is a
protein composed of three functional domains (Fig. 1A): a
dimerization domain (amino acids 1–32), a DNA-binding
domain (91–276), and a carboxyl-terminal transactivation
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FIG. 1. A: Spectrum of 136 somatic HNF1A mutations observed in 75 HCA samples (top) and in 364 MODY3 individuals (bottom) (data from Ellard
and Colclough [25]). Each arrow indicates a point mutation leading to a frameshift or a stop codon. Each bar indicates a point mutation leading
to an amino acid substitution. Œ, in-frame deletion; , in-frame duplication; F, mutation in splicing site. B: Comparison of the number of
substitutions and stops in different HNF1 domains. HCA (f) and MODY3 () histograms represent the percentage of total mutations observed
in each domain; substitutions and stops are represented in the upper part and the lower part, respectively. Signiﬁcant differences between HCA
and MODY3 individuals are indicated: *0.05 > P > 0.01; **0.01 > P > 0.001; ***P < 0.001. C: Comparison of the number of stops in the
transactivation domain (281–631) vs. the rest of the protein observed in individuals with HCA (f) and MODY3 (). ***Signiﬁcant difference (P <
0.001) between the two populations. D: Spectrum of eight germline HNF1A mutations identiﬁed in H-HCA (top) and ﬁve germline HNF1A
mutations identiﬁed in monoallelic mutated HCA (bottom). AA, amino acids.
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of a POU-S domain (91–181) and an atypical homeodomain
POU-H (203–280) formed by 3 -helices and an insertion of
21 amino acids between H2 and H3 (20). Most of the
HNF1A mutations observed in patients with HCA and
MODY3 are predicted to inactivate the protein function
(5,8,10,21,22). Correlations have been identiﬁed linking the
position of the mutations in HNF1A and the age of
diabetes onset, a phenomenon that can be explained by
the speciﬁc isoforms that are expressed in the fetal or
adult pancreas (21,22). Based on these data, we can
hypothesize that not all mutations demonstrate the same
effect on the HNF1 function.
In this study, we hypothesized that rare occurrence of
HCA in MODY3 may be caused by differences in the
somatic and germline spectra of mutations, both concern-
ing their origin and their functional consequences. To test
this hypothesis, we compared the spectrum of HNF1A
mutations identiﬁed in HCA with that identiﬁed in MODY3.
Then, taking advantage of working on human liver tissues
with mutations occurring under their endogenous pro-
moter, we evaluated the consequences of several HNF1
mutants at the mRNA expression and protein levels. We
also investigated the potential mechanism of HNF1A
mutagenesis by 1) comparing our observations with stud-
ies of a known genotoxic agent and 2) assessing the level
of oxidative stress in the liver.
RESEARCH DESIGN AND METHODS
A group of 14 university hospitals participated in this study and 72 patients
were recruited between 1992 and 2006. Individuals with conﬁrmed HNF1A-
mutated HCA who underwent curative resection of the tumor(s) were eligible
for inclusion in this study. The mean age of the patients was 37.5 years
(ranging from 14 to 66 years), and there were only seven male patients. Among
the women studied, 71% (34 of 48) had a history of oral contraception use, and
17 patients were missing this data. There were 89 HNF1A-mutated HCA
samples from 72 patients, although 44 samples had been reported previously
(8). In 10 patients with multiple and sporadic tumors, several nodules were
genotyped. For each patient, different somatic HNF1A mutations were
observed in the genotyped nodules. For all patients, a representative part of
the HCA nodule, as well as of the nontumor liver when it was available, was
immediately frozen in liquid nitrogen and stored at 80°C until used for
molecular studies. The study was conducted in accordance with French law
and institutional ethical guidelines. The Ethical Committee of the Saint-Louis
Hospital (Paris, France) approved the overall design of the study.
Mutation screening. In all 89 tumors, we sequenced the HNF1A gene using
direct sequencing of the exons on genomic DNA or RT-PCR to identify
mutation, as previously described (5). All identiﬁed mutations (Tables 1 and 2)
were conﬁrmed by two independent PCR ampliﬁcations of genomic DNA from
tumor, and corresponding nontumor tissues were systematically sequenced to
search for germline mutations. In samples with mutations affecting splicing
sites, we characterized the transcripts by sequence analysis of the mRNA
transcripts. In 37 H-HCA, the coding exons of MYH (exons 1–16) and OGG1
(exons 1–7) were screened for mutations by direct sequencing of PCR
products. Oligonucleotides used for all PCR reactions and experimental
conditions are listed in supplementary Tables 1 and 2 available in an online
appendix at http://care.diabetesjournals.org/cgi/content/full/db09-1819/DC1.
Allelic frequency of an OGG1 polymorphism observed in H-HCA was com-
pared with those obtained in a control group of non-HNF1A-mutated hepato-
cellular tumors (58 samples) as previously described (13) and presented in
supplementary Table 3 (available in an online appendix).
Quantitative RT-PCR. Total RNA was extracted using the RNeasy kit
(Qiagen, Valencia, CA) from all frozen samples of available HCA and
nontumor liver tissues. RNA isolated from 16 H-HCA and 24 nontumor
tissue samples was deemed to be of acceptable quality for quantitative
RT-PCR experiments (23). Speciﬁc assays for MYH (Hs01014866_g1),
OGG1 (Hs00213454m1), APE1 (Hs00172396_m1), POL (Hs00160263_m1),
FABP1 (Hs00155026_m1), UGT2B7 (Hs00426592_m1), and R18S (rRNA,
Hs99999901_s1) were obtained from Applied Biosystems (Foster City, CA).
The relative amount of target gene mRNAs was determined using the 2
CT
method (24). The values obtained for FABP1 and UGT2B7 were expressed as
the n-fold ratio of the gene expression in a tested sample as compared with
the mean of 11 nontumor tissues. Only six nontumor tissues from patients
with a H-HCA were used with the MYH, OGG1, APE1, and POL assays. The
values obtained were compared with the mean of seven nontumor tissues
from patients with a non-HNF1A–mutated HCA.
Western blotting. Western blot analyses were performed as described (9)
using two primary goat polyclonal anti-HNF1 antibodies (Santa Cruz Bio-
technology), one detecting the amino terminus, and the other detecting the
carboxy terminus of the protein (SC-6548 and SC-6547, respectively), used at
the dilution 1:500.
Determination of reduced and total glutathione levels. Approximatively
50 mg of frozen nontumor liver tissues were homogenized in 5% 5-sulfosali-
cylic acid. After centrifugation at 8,000g for 10 min, the supernatant was
assessed for reduced and total glutathione content with an ApoGSH Glutathi-
one Colorimetric Assay Kit (BioVision, Mountain View, CA), following the
manufacturer’s protocol.
Immunohistochemistry. Formalin-ﬁxed, parafﬁn-embedded sections (5 m)
were mounted on glass slides. Sections were deparafﬁnized in xylene,
rehydrated in a series of graded alcohol concentrations, and placed in PBS
with 0.1% Tween 20. Immunostaining was performed using a DAKO EnVision
System horseradish peroxidase (Dako Cytomation, Carpinteria, CA) kit using
primary antibody (1:2,000 dilution in PBS containing 1% BSA, incubated
overnight at 4°C) against 4-hydroxynonenal protein adducts (Alpha Diagnos-
tics, San Antonio, TX). Slides were counterstained with hematoxylin and
mounted with glass coverslips.
Statistical analysis. Statistical analysis was performed using GraphPad
Prism software (version 4, GraphPad Software, San Diego, CA). Allelic
frequencies of the OGG1 polymorphism in H-HCA and the group control were
compared using contingency tables with a Fisher exact test.
RESULTS
Spectrum of HNF1A mutations in HCA differs from
that in MODY3. Among 89 HCA samples with HNF1A
alteration, mutations and deletion were biallelic in 84
(94%) samples. To further analyze the spectrum of HNF1A
mutations, we included 151 HNF1A alterations with a ﬁrm
somatic origin identiﬁed in 75 different HCAs; in contrast,
all samples with a proven or highly suspected germline
mutation were excluded from this ﬁrst analysis (Fig. 1A).
Among 151 HNF1A somatic alterations, 90% were point
mutations, and the remaining 10% (15 of 151) were gene
deletions as evidenced by the loss of heterozygosity at a
HNF1A single nucleotide polymorphism(s) compared with
the corresponding nontumor tissues. Among the muta-
tions, 57 were missense, 62 were frameshift and nonsense,
and 12 were mutations affecting a splicing site. The ﬁve
remaining mutations were small in-frame deletions or
duplication (Fig. 1A, Table 1).
Next, we compared the spectrum of somatic HNF1A
mutations identiﬁed in HCA with 364 germline mutations
previously described in individuals with MODY3 without
HCA (Fig. 1A, lower panel, supplementary Table 4, avail-
able in an online appendix) and by Ellard and Colclough
(25). In both HCA and MODY3, a hotspot mutation at
codon 291 was present, whereas a hotspot mutation at
codon 206 was speciﬁcally identiﬁed in HCA (Fig. 1A). As
previously reported, codon 291 mutation is located in a
polyC-8 tract, whereas codon 206 mutation is not located
in a repeated sequence motif. Because codon 291 muta-
tions represented 20% of the mutations in both spectra, we
did not include them in the following analysis. There was
no signiﬁcant difference (P  0.16) in the proportion of
missense and truncating (frameshift, nonsense, and muta-
tions affecting a splicing site) mutations in MODY3 and
HCA spectra. Thus, there were 63 and 55% of missense
mutations in MODY3 and HCA, respectively, and 37 and
45% of truncating mutations in MODY3 and HCA, respec-
tively. In contrast, the distribution of the mutations was
signiﬁcantly different in HCA compared with the MODY3
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Biallelic HNF1 mutations identiﬁed in HCA
No.
Tumor tissue
Allele 1 Allele 2
Somatic origin
154* 872–873insC, P291fs† 749AC, Q250P
196* 379 AT, N127Y 495GT, W165C
357*‡ IVS2 	 1GA, W165X† 618GT, W206C
358*‡ 617GT, W206L 872–884del, P291fs
368*‡ 710AG, N237S LOH
369*‡ 436–437delC, Q146fs LOH
370*‡ 872–873insC, P291fs† 803TG, F268C
371*‡ 617GT, W206L 730AG, R244G
373*‡ 82CT, Q28X† LOH
380‡ 196GT, E66X 779CT, T260M†
383‡ 493TA, W165R 1340CT, P447L†
384* 17–35insT, 7–12del 26–32del, Q9fs
385*‡ 817AG, K273E LOH
461‡ 872–873insC, P291fs† 872–873delC, P291fs†
462‡ 632AC, Q211P 670CG, P224A
463 632AC, Q211P 617GT, W206L
464‡ 71–82del, A25-Q28del 747–764del, Q250-G255del
474‡ 617GT, W206L LOH
476‡ 232–245dup, T81fs 1,288–1289delG, G430fs
496 872–873insC, P291fs† 796–798dup, N266dup
508‡ 77TA, L26Q 872–873delC, P291fs†
516‡ 185–194del, N62fs 788GA, R263H†
532‡ 198–202del, T67fs 618GT, W206C
535‡ 617GT, W206L 872–873insC, P291fs†
539‡ 686GA, R229Q† 775GC, V259L
540‡ 618GT, W206C LOH
546‡ 1 AG, M1X 620GA, G207D†
575‡ IVS2 	 1 del13 956–957delG, G319fs
578 788 GT, R263L† IVS5 	 1G T
579 132–156del, D45fs 872–873insC, P291fs†
583‡ 811–818del, R271fs 815GA, R272H†
584‡ 607CT, R203C† 710AG, N237S
591‡ 787CT, R263S LOH
592‡ 526CT, Q176X† IVS5–2 AG†
621 711 TG, N237K 872–873insC, P291fs†
633 872–873insC, P291fs† 650–654del, A217fs
635 618GC, W206C 872–873insC, P291fs†
682‡ 197–198insA, T67fs 872–873insC, P291fs†
683 695–697del, V233del 613 AC, K205Q†
687‡ 814CA, R272S† LOH
688 710AG, N237S LOH
689 IVS1 	 2delTA 56 CA, S19X
690 IVS1–2 AT 872–873insC, P291fs†
694‡ 682GT, E228X IVS2–2 AG
695 105–144delinsTTC, P35fs IVS2–2 AG
696‡ 872–873insC, P291fs† 1168GT, E390X
699‡ 685CG, R229G 710–711insA, N237fs
705‡ 618GT, W206C 631CT, Q211X
749 618GT, W206C LOH
759 IVS2 	 1G A† 608GT, R203L
761 617GT, W206L 618–628del, W206fs
762 IVS2 	 1G A† LOH
763 872–873insC, P291fs† IVS2 	 1G A†
778 1,067–1073del7, L356fs 1441CT, Q481X
785 108CA, Y36X 570–577del, T191fs
806 618GT, W206C 872–873insC, P291fs†
814 476GA, R159Q† 872–873insC, P291fs†
815 779CT, T260M† 872–873insC, P291fs†
816 872–873insC, P291fs† IVS3 	 8, insAGT, dup637-IVS3 	 7
817 196GT, E66X 711TA, N237K
Continued on facing page
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were restricted to the POU-H domain (P 
 0.001) in HCA,
they were distributed in all HNF1 domains in individuals
with MODY3 (Fig. 1B). Also, in HCA, truncating mutations
were localized predominantly in the ﬁrst 280 amino acids
(P 
 0.001), whereas they were distributed equally be-
tween the ﬁrst 280 amino acids and the transactivation
domain in the individuals with MODY3 (Fig. 1C).
Germline HNF1A mutations are found in H-HCA or in
other subtypes of adenomas. In a second step, we
analyzed the distribution of the 13 germline HNF1A mu-
tations identiﬁed in patients with adenomas. In eight
patients, we identiﬁed a mutation of the second HNF1A
allele in the corresponding tumor leading to a biallelic
inactivation of HNF1 (Table 1). The corresponding germ-
line mutations ﬁt the distribution of the somatic HNF1A
mutations: six of them were nonsense or frameshift occur-
ring before codon 292, and the remaining two mutations
were missense affecting codon 272, an amino acid found to
be mutated by a somatic event (Fig. 1D). In contrast, in
four HCA samples [372 (R583Q), 769 (T525S), 966 (L389V),
and 998 (R278Q)], we observed a germline HNF1A muta-
tion without alteration of the second HNF1A allele. All of
these germline mutations were missense; three of them
localized in the transactivation domain, and the last one
was at the end of the POU-H domain. None of these
mutations were described in the spectrum of somatic
HNF1A mutations; however, three of them (R583Q, T525S,
and L389V) have been previously reported in individuals
with MODY3 (21,25). Thus, these four germline mutations
did not ﬁt the characteristic distribution of the somatic
one. Moreover, the corresponding adenomas were classi-
ﬁed in different molecular subgroups of HCA: one of them
was -catenin activated (case 372), two were inﬂamma-
tory adenomas with or without a gp130 activating muta-
tion (cases 769 and 966), and the last one remained
unclassiﬁed (case 998).
Functional consequences of HNF1A mutations in
HCA. Most of the somatic mutations found in HCA are
predicted to inactivate the protein because they are almost
all biallelic and frequently nonsense or missense affecting
the POU-H domain that is essential for DNA binding. We
also analyzed the consequence of seven mutations that
affected different splice sites. All of these mutations re-
sulted in aberrant splicing, the outcome of which is either
an aberrant protein with an early stop (Fig. 2A, B, and D),
or a protein with an amino acid replacement and a deletion
of ﬁve amino acids in the DNA-binding domain (Fig. 2C).
TABLE 1
Continued
No.
Tumor tissue
Allele 1 Allele 2
818 710AG, N237S 872–873delC, P291fs†
829 695TA, L232Q 931–932delGinsACCTA, A311fs
831 815GA, R272H† 872–873insC, P291fs†
833 607CT, R203C† LOH
850 872–873insC, P291fs† 133–149del, D45fs
851 872–873delC, P291fs† LOH
856 872–873delC, P291fs† 770AC, N257T
957 730AG, R244G 1,274–1275delC, T425fs
964 629CT, S210F LOH
971 620GA, G207D† 872–873delC, P291fs†
972 618GT, W206C 1,249–1250insT, G417fs
1,025 97–103del, P33fs 872–873insC, P291fs†
Germline origin (allele 1)
340*‡ 685C>T, R229X† LOH
487‡ 814 C>A, R272S† LOH
509‡ 391C>T, R131W† 872–873delC, P291fs†
514‡ 829–837del, F277-H279 872–873insC, P291fs†
518‡ 164–168del, G55fs† LOH
523‡ 872–873insC, P291fs† LOH
590‡ 257–258delT, L86fs IVS2 	 1G T
965 252–258del, I85fs 815GA, R272H†
Undetermined origin
479‡ 476–479del, R159Pfs 811CT, R271W†
482‡ 653 AG, Y218C† LOH
489‡ IVS1–2 AT 1,072–1073delCins11, P358fs
548 IVS1–1 GT 1,072–1073delCins11, P358fs
951 534–535insA, H179fs 779CT, T260M†
Cases of HCA were previously described in *Bluteau et al. (5) or ‡Zucman-Rossi et al. (8). MODY3 mutations were previously described in
†Ellard and Colclough (25) or Bellanne ´-Chantelot et al. (21). Case 535 has a third somatic mutation, 51–60delins6, S19fs. Boldface indicates
allele 1. del, deletion; fs, frameshift; IVS, intervening sequence; LOH, loss of heterozygosity; ins, insertion; Nm, nonmutated.
TABLE 2
Germline HNF1 mutations in monoallelic mutated HCA
No. Allele 1 Allele 2
372*† 1748GA, R583Q‡ Nm
769 1573AT, T525S§ Nm
966 1165TG, L389V§ Nm
998 833GA, R278Q Nm
Cases of HCA were previously described in *Bluteau et al. (5) or
‡Zucman-Rossi et al. (8). MODY3 mutations were previously de-
scribed in †Ellard and Colclough (25) or Bellanne ´-Chantelot et al.
(21). Nm, nonmutated.
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HCA and compared it with that in nontumor tissue.
Samples with mutations leading to an early stop contained
little detectable HNF1 protein (supplementary Fig. 1,
available in an online appendix; samples identiﬁed with
arrows and data on gradient migration, not shown). Addi-
tionally, some samples harboring missense mutations ex-
hibited a dramatic increase in the expression of HNF1
compared with normal liver (supplementary Fig. 1).
The HNF1 transcription factor regulates expression of
several key liver genes, including UGT2B7 and FABP1
(16,18). Indeed, a shutdown of mRNA expression for these
target genes was observed in all patients with HCAs tested
with biallelic HNF1A mutations, as previously reported
(4). An effect of monoallelic HNF1 mutants on expres-
sion of UGT2B7 and FABP1 has not been previously
examined in liver tissues. Our data show that monoal-
lelic mutations did not affect expression of FABP1 and
UGT2B7, which is not in favor of a dominant-negative
effect (Fig. 3). However, these results cannot completely
exclude a subtle dosage effect or a low dominant effect.
HNF1A mutations in HCA are likely to arise due to a
genotoxic event. In contrast to other solid tumors, point
mutations were much more frequent in HCA than were
chromosome deletions. The latter were found in only 10%
of the patients with HCAs. Among the point mutations in
HCA, we analyzed the proportion of different HNF1A
nucleotide changes and found that G-to-T transversions,
accounting for 36% of the cases, were the most common
type (Fig. 4A). Moreover, the distribution of nucleotide
substitution subtypes in H-HCA was strikingly different
from that in MODY3 (Fig. 4B) but very similar to a
spectrum of mutations known to be induced by genotoxic
events, that is, in TP53-mutated lung cancers in smokers
(Fig. 4C) (26). In addition, when the HNF1A nucleotide
substitutions were partitioned between the two DNA
strands, we observed that G-to-T transversions were sig-
niﬁcantly more frequent on a nontranscribed strand (P 
0.01) (Fig. 4D). Taking these results together, we suggest
that HNF1A somatic mutations showed a typical spectrum
of mutations induced by the genotoxic exposure targeting
a speciﬁc nucleotide sequence.
HNF1A spectrum of mutation is not related to mea-
surable increase in oxidative stress in liver. Because
both direct DNA damage by an environmental agent and
oxidative stress are known to result in G-to-T transversion
mutations (27,28), we also assessed oxidative stress mark-
ers in nontumor liver from six patients with H-HCA and
seven patients with non-HNF1A–mutated HCA (supple-
mentary Fig. 2, available in an online appendix). We
observed no difference in total or reduced glutathione
content, expression of four base excision DNA repair
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droxynonenal protein adducts, a marker of lipid peroxida-
tion (supplementary Fig. 3), between these two groups.
These data showed a lack of evidence for elevated oxida-
tive stress in livers of patients with H-HCA as a potential
source of DNA mutations.
In addition, it is possible that a large number of G-to-T
transversions could be caused by inefﬁcient repair of DNA
damage due to mutations or polymorphisms in MYH and
OGG1, genes involved in the repair of 8-hydroxyguanine
(30–32). Thus, we sequenced MYH and OGG1 DNA in 37
subjects with an HNF1A-mutated HCA, and no mutations
were detected in either gene. A known functional polymor-
phism in OGG1 (S326C) was detected in HNF1A-mutated
HCA subjects, albeit there was no difference in the fre-
quency of this polymorphism compared with that in con-
trol subjects (supplementary Table 3, available in an
online appendix).
DISCUSSION
In this study we analyzed the spectrum of HNF1A muta-
tions in HCA and showed a signiﬁcant difference in pattern
in comparison with individuals with MODY3, both at the
nucleotide and amino acid levels. In HCA, location of
the mutations is very restricted because almost all of the
truncating mutations led to the loss of the transactivation
domain and the missense mutations altered mainly the
POU-H domain. When we take into account the two largest
series of HNF1A screening in MODY3 (21,25), only 48% of
the germline mutations (117 of 720 are missense mutations
in POU-H, and 227 of 720 are truncating mutations local-
ized in the ﬁrst 291 amino acids) ﬁt the features of the
HNF1A somatic mutations. This observation suggests that
only a part of HNF1A mutations that are associated with
diabetes could predispose to the development of a H-HCA.
Previous analysis of the MODY3 mutations showed that
the age at onset of diabetes is modulated according to the
position of the mutation relative to the HNF1A isoforms:
missense mutations located in exons 7 to 10 that affect
only A or B isoforms of HNF1A are associated with the
late onset of diabetes (21,22). Interestingly, these muta-
tions are predicted to have a less severe effect on the
HNF1 function and are not found in HCA. Similarly, we
can hypothesize that frequent MODY3 missense mutations
located outside the POU-H domain and mutations truncat-
ing HNF1 after codon 291 are possibly less inactivating
than the mutations found in HCA. In contrast to MODY3, in
HCA the lack of mutations leading to amino acid substi-
tution in POU-S suggests that the POU-S and POU-H
domains are functionally different. Chi et al. (20) found
that the POU-S domain interacts with the POU-H domain
in the recognition and binding on promoter sequences;
however, the POU-S domain is not conserved in ho-
meobox transcription factors outside the POU family.
Thus, based on the proﬁle of the HNF1A mutations that
occur in HCA, it may be of interest to reanalyze clinical
severity of the diabetes and putative associated pheno-
types in patients with MODY3, taking into the account only
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POU-H, and mutations affecting splicing sites from exon 1
to 7.
Interestingly, among the ﬁve HCAs with a monoallelic
germline HNF1A mutation, three of them were inﬂamma-
tory. We previously noted that inﬂammatory adenomas are
associated with obesity (4), and the present observation
raised the question of an association with MODY3 and
possibly with other subtypes of adenomas. We can hypoth-
esize that according to the nature of their HNF1A germline
mutation, patients with MODY3 could be at risk of differ-
ent subtypes of HCA: mutations leading to a severe
impaired HNF1 function predispose to the development
of H-HCA, whereas germline mutation with a mild func-
tional consequence could predispose to inﬂammatory or
ß-catenin–activated HCAs without a familial context. In
consideration of the high risk of malignant transformation
of the -catenin-activated HCA, this observation could
have important clinical consequences.
Our analysis of the expression of mutant HNF1 pro-
teins in liver tissue did not reveal a detectable level of
truncated proteins, and most of the mutated proteins were
not expressed. Moreover, mutations of both HNF1A al-
leles are required to observe a downregulation of the
genes physiologically regulated by HNF1. These observa-
tions suggest that if a dominant-negative effect exists, as
suggested by the in vitro analyses for particular HNF1A
mutants (15), it is not sufﬁcient to shut down activity of
HNF1 in vivo. Accordingly, other researchers (33,34),
including Harries et al. (35) showed that HNF1A tran-
scripts harboring a premature termination codon (PTC)
were less expressed in lymphoblastoid cells than the
normal allele resulting from a “nonsense-mediated mRNA
decay,” which detects and degrades the transcripts with a
PTC to prevent the synthesis of truncated proteins. In the
present study, we observed a decrease of mRNA expres-
sion for 16 of 21 different mutants leading to PTC (data not
shown). Altogether, in hepatocytes, a dominant-negative
effect of an HNF1 mutant is unlikely in vivo.
This study not only conﬁrms, in a large series of
adenomas, that the spectrum of HNF1A mutations in HCA
is different from that in individuals with MODY3, it also
supports the hypothesis that HNF1A mutations in HCA
arise because of a genotoxic mechanism. First, we ob-
served a consistent hotspot mutation at the codon 206 of
HNF1A in HCA. Hotspots of transversion identiﬁed in
tumors without a repeated nucleotide sequence context
were previously suggested to be a hallmark of an exposure
to a genotoxic compound, such as an R249S mutation in
the TP53 gene in hepatocellular carcinoma (HCC) associ-
ated with an exposure to the aﬂatoxin B1 mycotoxin
(36,37).
Second, Hainaut and Pfeifer (26) showed that there is a
signiﬁcant difference in the pattern of TP53 mutations in
lung cancers between smokers and nonsmokers, with a
30% frequency of G-to-T transversions in smoking-related
lung cancer vs. 10% in non-smoking–related lung cancer.
The overabundance of G-to-T transversions in smoking-
related lung cancers was consistent with the studies of
DNA damage and mutations due to benzo[a]pyrene and
other cigarette smoke-derived carcinogens and their me-
tabolites (38,39). Our observation of an uneven distribu-
tion among HNF1A nucleotide substitutions in HCA and
high frequency of G-to-T transversions is in many ways
similar to that in lung cancer caused by tobacco (Fig. 4A).
Third, Denissenko et al. (40) showed that the repair of
benzo[a]pyrene diol epoxide adducts in the nontran-
scribed strand was slower than that in the transcribed
strand and may explain the strand bias of transversions in
cancer. Similarly, we observed that G-to-T transversions
were signiﬁcantly localized to the nontranscribed strand in
H-HCA, an additional argument in favor of a genotoxic
effect and, possibly, a presence of bulky DNA adducts.
Finally, the origin of such a genotoxic signature remains
to be elucidated. We can hypothesize that it could be
related to a particular genetic susceptibility and/or to an
exposure to a speciﬁc toxic. According to the ﬁrst hypoth-
esis, we searched for mutations in OGG1 and MYH, both
genes speciﬁcally involved in the repair of 8-hydroxygua-
nine, a product of oxidative DNA damage that can also
lead to G-to-T transversions (30–32). However, we did not
observe mutations in these genes in patients with HCAs. In
addition, we did not observe a higher level of oxidative
stress in the livers of patients with a H-HCA. These results
strongly suggest that exposure to an environmental agent
appears to be the most likely event to explain the elevated
rate of G-to-T transversions in H-HCA. Because HCA
occurrence is highly associated with oral contraception,
we can hypothesize that estrogen exposure could play a
role in this mechanism. This last hypothesis is supported
by the facts that 1) the genotoxic activity of estrogen
metabolites has been shown, particularly for catechol
estrogens that may be oxidized to a reactive quinone
capable of direct formation of DNA adducts (41,42); and 2)
germline heterozygous mutations of CYP1B1, a key me-
tabolism enzyme responsible for the formation of hydroxy-
lated and genotoxic metabolites of estrogen, contribute to
the development of H-HCA in women using hormonal
contraception (13).
In conclusion, when analyzing a large series of individ-
uals with HCAs, we observed a signiﬁcant differences
between HNF1A somatic mutations identiﬁed in those
with HCAs and the germline mutations identiﬁed in indi-
viduals with MODY3. Somatic mutations in HCA predict a
more inactivating proﬁle, resulting in a complete loss of
function of the protein when biallelic. Moreover, we
showed that the origin of the mutations might be the result
of DNA damage caused by a genotoxic agent, possibly
resulting from the metabolism of estrogen that could also
be associated with a genetic susceptibility that remains to
be identiﬁed.
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